keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/28525899/the-prognostic-value-of-long-noncoding-rnas-in-prostate-cancer-a-systematic-review-and-meta-analysis
#1
Weijie Ma, Xi Chen, Lu Ding, Jianhong Ma, Wei Jing, Tian Lan, Haseeb Sattar, Yongchang Wei, Fuling Zhou, Yufeng Yuan
The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28521303/emt-circulating-tumor-cells-detected-by-cell-surface-vimentin-are-associated-with-prostate-cancer-progression
#2
Arun Satelli, Izhar Batth, Zachary Brownlee, Abhishek Mitra, Shouhao Zhou, Hyangsoon Noh, Christina R Rojas, Heming Li, Qing H Meng, Shulin Li
Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs...
May 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28515807/external-validation-of-the-procars-nomograms-and-comparison-of-existing-risk-stratification-tools-for-localized-prostate-cancer
#3
David Tiberi, George Rodrigues, Tom Pickles, Jim Morris, Juanita Crook, Andre-Guy Martin, Fabio Cury, Charles Catton, Himu Lukka, Andrew Warner, Daniel Taussky
INTRODUCTION: The purpose of this study was to perform a direct comparison of several existing risk-stratification tools for localized prostate cancer in terms of their ability to predict for biochemical failure-free survival (BFFS). Two large databases were used and an external validation of two recently developed nomograms on an independent cohort was also performed in this analysis. METHODS: Patients who were treated with external beam radiotherapy (EBRT) and/or brachytherapy for localized prostate cancer were selected from the multi-institutional Genitourinary Radiation Oncologists of Canada (GUROC) Prostate Cancer Risk Stratification (ProCaRS) database (n=7974) and the Centre Hospitalier de l'Université de Montréal (CHUM) validation database (n=2266)...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28494073/associations-of-luminal-and-basal-subtyping-of-prostate-cancer-with-prognosis-and-response-to-androgen-deprivation-therapy
#4
Shuang G Zhao, S Laura Chang, Nicholas Erho, Menggang Yu, Jonathan Lehrer, Mohammed Alshalalfa, Corey Speers, Matthew R Cooperberg, Won Kim, Charles J Ryan, Robert B Den, Stephen J Freedland, Edwin Posadas, Howard Sandler, Eric A Klein, Peter Black, Roland Seiler, Scott A Tomlins, Arul M Chinnaiyan, Robert B Jenkins, Elai Davicioni, Ashley E Ross, Edward M Schaeffer, Paul L Nguyen, Peter R Carroll, R Jeffrey Karnes, Daniel E Spratt, Felix Y Feng
Importance: There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies. Objectives: To identify prostate cancer subtypes based on luminal and basal lineage and to determine associations with clinical outcomes and response to treatment. Design, Setting, and Participants: The PAM50 classifier was used to subtype 1567 retrospectively collected (median follow-up, 10 years) and 2215 prospectively collected prostate cancer samples into luminal- and basal-like subtypes...
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28486040/gata2-expression-and-biochemical-recurrence-following-salvage-radiation-therapy-for-relapsing-prostate-cancer
#5
Jessica L Robinson, Katherine S Tzou, Alexander S Parker, Michael G Heckman, Kevin J Wu, Tracy W Hilton, Thomas M Pisansky, Steven E Schild, Jennifer L Peterson, Laura A Vallow, Steven J Buskirk
OBJECTIVES: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy (RP), however has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after RP. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumor samples and risk of BCR after SRT. METHODS: 109 men who were treated with SRT were included...
May 9, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28484728/pretreatment-prostate-specific-antigen-doubling-time-as-prognostic-factor-in-prostate-cancer-patients
#6
Gennady M Zharinov, Oleg A Bogomolov, Natalia N Neklasova, Vladimir N Anisimov
Despite the prostate-specific antigen (PSA) serum level commonly uses as tumor marker in diagnosis of prostate cancer, it seems that PSA doubling time (PSADT) could be more useful indicator of tumor behavior and of prognosis for patients. The results of hormone and radiation therapy were evaluated for 912 prostate cancer having at least 2 PSA tests before the treatment was started. Clustering procedure (selection of homogenous group) was performed by using PSADT as the classification marker. The rate of PSADT was estimated for different dissemination rate, age, Gleasons's score and education level...
January 2017: Oncoscience
https://www.readbyqxmd.com/read/28479874/prognostic-correlation-of-cell-cycle-progression-score-and-ki-67-as-a-predictor-of-aggressiveness-biochemical-failure-and-mortality-in-men-with-high-risk-prostate-cancer-treated-with-external-beam-radiation-therapy
#7
Iván Henríquez López, David Parada, Pablo Gallardo, Marina Gascón, Arnau Besora, Karla Peña, Francesc Riu, Miquel Arquez Pianetta, Oscar Abuchaibe, Laura Torres Royò, Meritxell Arenas
OBJECTIVES: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). METHODS: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006...
May 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28476530/enriching-gene-expression-profiles-will-help-personalize-prostate-cancer-management-for-african-americans-a-perspective
#8
REVIEW
Srinivasan Vijayakumar, John C Henegan, Xu Zhang, Wanmei Wang, William A Day, Vani Vijayakumar, Carlos S Moreno, Christian R Gomez
Prostate cancer (PCa) remains the most common form of cancer affecting men in the Western Hemisphere. Mortality rate is 130% higher among African-American men (AAM) than Caucasian-American men. As this trend is not new nor changing, there is an urgent need to identify markers with the ability to specifically distinguish aggressive PCa in the context of race. Gene expression patterns have been used as a tool to identify prognostic biomarkers for PCa to help reduce this disparity. Gene expression profiles reveal molecular mechanisms useful in understanding the biologic basis of tumorigenesis...
May 2, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28475401/cellular-identity-crisis-antiandrogen-resistance-by-lineage-plasticity
#9
Daniel Tuerff, Tristan Sissung, William D Figg
A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.
May 5, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28469484/preoperative-serum-carcinoembryonic-antigen-as-a-marker-for-predicting-the-outcome-of-three-cancers
#10
Jingzhu Nan, Juan Li, Xiujuan Li, Guanghong Guo, Xinyu Wen, Yaping Tian
BACKGROUND: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. OBJECTIVE: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. METHODS: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index...
2017: Biomarkers in Cancer
https://www.readbyqxmd.com/read/28467610/apurinic-apyrimidinic-endonuclease-1-ape1-ref-1-overexpression-is-an-independent-prognostic-marker-in-prostate-cancer-without-tmprss2-erg-fusion
#11
Manuela Juhnke, Asmus Heumann, Viktoria Chirico, Doris Höflmayer, Anne Menz, Andrea Hinsch, Claudia Hube-Magg, Martina Kluth, Dagmar S Lang, Christina Möller-Koop, Guido Sauter, Ronald Simon, Burkhard Beyer, Raisa Pompe, Imke Thederan, Thorsten Schlomm, Andreas M Luebke
Polymorphisms of the base excision repair gene APE1 may be associated with an increased risk for developing prostate cancer. In other cancer types, altered APE1 protein expression is a candidate prognostic marker. Using immunohistochemistry, we thus analyzed APE1 expression in 9,763 prostate cancers in a tissue microarray (TMA) with attached clinical and molecular data. The comparison with normal prostate tissue revealed an upregulation of APE1 in cancer samples. APE1 immunostaining was considered weak in 20...
May 3, 2017: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/28460462/the-prognostic-role-of-immune-checkpoint-markers-programmed-cell-death-protein-1-pd-1-and-programmed-death-ligand-1-pd-l1-in-a-large-multicenter-prostate-cancer-cohort
#12
Nora Ness, Sigve Andersen, Mehrdad Rakaee Khanehkenari, Cecilie V Nordbakken, Andrej Valkov, Erna-Elise Paulsen, Yngve Nordby, Roy M Bremnes, Tom Donnem, Lill-Tove Busund, Elin Richardsen
Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28453701/an-exploratory-analysis-of-alkaline-phosphatase-lactate-dehydrogenase-and-prostate-specific-antigen-dynamics-in-the-phase-3-alsympca-trial-with-radium-223
#13
O Sartor, R E Coleman, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, N J Vogelzang, Ø Bruland, S Kobina, S Wilhelm, L Xu, M Shan, M W Kattan, C Parker
Background: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. Patients and methods: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28423666/negative-lc3b-immunoreactivity-in-cancer-cells-is-an-independent-prognostic-predictor-of-prostate-cancer-specific-death
#14
Ashkan Mortezavi, Souzan Salemi, Niels J Rupp, Jan Hendrik Rüschoff, Thomas Hermanns, Cedric Poyet, Marco Randazzo, Hans-Uwe Simon, Holger Moch, Tullio Sulser, Peter Wild, Daniel Eberli
BACKGROUND: Autophagy is a catabolic cellular process used for degradation of cytoplasmic organelles and preservation of cell viability. In this study we aimed to analyse the level of autophagy markers in benign and malignant prostate tissue and to evaluate the prognostic properties for patients with prostate cancer (PCa). RESULTS: LC3b expression was significantly upregulated in PCa, especially in metastatic and castration-resistant PCa samples compared to benign prostate tissue (p<0...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28418894/urinary-rkip-p-rkip-is-a-potential-diagnostic-and-prognostic-marker-of-clear-cell-renal-cell-carcinoma
#15
Massimo Papale, Grazia Vocino, Giuseppe Lucarelli, Monica Rutigliano, Margherita Gigante, Maria Teresa Rocchetti, Francesco Pesce, Francesca Sanguedolce, Pantaleo Bufo, Michele Battaglia, Giovanni Stallone, Giuseppe Grandaliano, Giuseppe Carrieri, Loreto Gesualdo, Elena Ranieri
Clear cell Renal Cell Carcinoma (ccRCC) causes over 13,000 deaths each year, and about 20,000 new cases/year in Europe. In most cases, the causes are unknown and, most importantly, there are no reliable biomarkers for the diagnosis and prognosis of this disease. The search for sensitive biomarkers for early diagnosis and prognosis of clear cell Renal Cell Carcinoma (ccRCC) is currently a fast growing field. We carried out proteomics analysis of 93 urinary samples of healthy subjects (HS) and patients affected by ccRCC, prostate cancer (PCa) and chronic kidney disease (CKD), that was able to successfully distinguish each group...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415558/family-with-sequence-similarity-13c-fam13c-overexpression-is-an-independent-prognostic-marker-in-prostate-cancer
#16
Christoph Burdelski, Laura Borcherding, Martina Kluth, Claudia Hube-Magg, Nathaniel Melling, Ronald Simon, Christina Möller-Koop, Philipp Weigand, Sarah Minner, Alexander Haese, Hans Uwe Michl, Maria Christina Tsourlakis, Frank Jacobsen, Andrea Hinsch, Corinna Wittmer, Patrick Lebok, Stefan Steurer, Jakob R Izbicki, Guido Sauter, Till Krech, Franziska Büscheck, Till Clauditz, Thorsten Schlomm, Waldemar Wilczak
FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28410213/brca2-mutations-should-be-screened-early-and-routinely-as-markers-of-poor-prognosis-evidence-from-8-988-patients-with-prostate-cancer
#17
Ming Cui, Xian-Shu Gao, Xiaobin Gu, Wei Guo, Xiaoying Li, Mingwei Ma, Shangbin Qin, Xin Qi, Mu Xie, Chuan Peng, Yun Bai
The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa. We searched relevant articles from PubMed, Embase, Web of Science, and the Cochrane Library databases to evaluate the differences in the overall survival (OS) and cancer-specific survival (CSS) between BRCA2 mutation carriers and non-carriers in patients with PCa...
March 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28410117/racial-disparities-disruptive-genes-in-prostate-carcinogenesis
#18
Savita Singh, Alexis Plaga, Girish C Shukla
Population specific studies in prostate cancer (PCa) reveal a unique heterogeneous etiology. Various factors, such as genetics, environment and dietary regimen seems to determine disease progression, therapeutic resistance and rate of mortality. Enormous disparity documented in disease incidences, aggressiveness and mortality in PCa among AAs (African Americans) and CAs (Caucasian Americans) is attributed to the variations in genetics, epigenetics and their association with metabolism. Scientific and clinical evidences have revealed the influence of variations in Androgen Receptor (AR), RNAse L, macrophage scavenger receptor 1 (MRS1), androgen metabolism by cytochrome P450 3A4, differential regulation of microRNAs, epigenetic alterations and diet in racial disparity in PCa incidences and mortality...
June 1, 2017: Frontiers in Bioscience (Scholar Edition)
https://www.readbyqxmd.com/read/28389514/histopathology-of-prostate-cancer
#19
Peter A Humphrey
This review focuses on histopathological aspects of carcinoma of the prostate. A tissue diagnosis of adenocarcinoma is often essential for establishing a diagnosis of prostate cancer, and the foundation for a tissue diagnosis is currently light microscopic examination of hematoxylin and eosin (H&E)-stained tissue sections. Markers detected by immunohistochemistry on tissue sections can support a diagnosis of adenocarcinoma that is primary in the prostate gland or metastatic. Histological variants of carcinoma of the prostate are important for diagnostic recognition of cancer or as clinicopathologic entities that have prognostic and/or therapeutic significance...
April 7, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/28382925/combined-analysis-of-crmp4-methylation-levels-and-capra-s-score-predicts-metastasis-and-outcomes-in-prostate-cancer-patients
#20
Qun-Xiong Huang, Chu-Tian Xiao, Zheng Chen, Min-Hua Lu, Jun Pang, Jin-Ming Di, Zi-Huan Luo, Xin Gao
The present study analyzed the predictive value of combined analysis of collapsin response mediator protein 4 (CRMP4) methylation levels and the Cancer of the Prostate Risk Assessment (CAPRA-S) Postsurgical score of patients who required adjuvant hormone therapy (AHT) after radical prostatectomy (RP). We retrospectively analyzed 305 patients with prostate cancer (PCa) who received RP and subsequent androgen deprivation therapy (ADT). Two hundred and thirty patients with clinically high-risk PCa underwent immediate ADT, and 75 patients with intermediate risk PCa underwent deferred ADT...
April 4, 2017: Asian Journal of Andrology
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"